Clinical trials
1 active trial in Japan
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)Japan NAD+ Supplements Market Industry Trends and Forecast to 2034: Segmented by (Ingredient, Form, Distribution Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$67.3 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $36.8 Mn | — | — |
| 2025 (base) | $41.0 Mn | +$4.2 Mn | — |
| 2026 (forecast) | $45.6 Mn | +$4.7 Mn | +11.4% |
| 2027 (forecast) | $50.8 Mn | +$5.2 Mn | +24.1% |
| 2028 (forecast) | $56.6 Mn | +$5.8 Mn | +38.2% |
| 2029 (forecast) | $63.1 Mn | +$6.5 Mn | +54% |
| 2030 (forecast) | $70.3 Mn | +$7.2 Mn | +71.6% |
| 2031 (forecast) | $78.3 Mn | +$8.0 Mn | +91.1% |
| 2032 (forecast) | $87.2 Mn | +$8.9 Mn | +112.9% |
| 2033 (forecast) | $97.1 Mn | +$9.9 Mn | +137.2% |
| 2034 (forecast) | $108.2 Mn | +$11.1 Mn | +164.2% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
NAD+ supplements, such as NMN and nicotinamide riboside, aim to raise levels of NAD+, a molecule linked to cell energy that falls with age.
Key segments of the NAD+ Supplements market include ingredient (Nicotinamide Riboside, NMN and NAD+ Direct) and form (Capsules, Powders and IV and Injections).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the NAD+ Supplements market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the NAD+ Supplements market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the NAD+ Supplements market.
The NAD+ Supplements market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Food and supplement rules, labelling and health-claim regulations govern NAD+ Supplements products. Authorities such as the US FDA, EFSA and national food safety bodies set what can be sold and claimed in Japan.
What doctors and scientists are doing in NAD+ Supplements right now, from free public sources.
1 active trial in Japan
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.
[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
From our blog
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Japan · 2 shared keywords
Healthcare Services · Japan
Digital Health · Japan
Pharmaceuticals · Japan
Medical Devices · Japan
Medical Devices · Japan
Medical Devices · Japan